What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report Eli Lilly's financial results for the second quarter ended June 30, 2008, and to provide updated full-year 2008 financial expectations. It also highlights the company's use of non-GAAP financial measures.

Why is Eli Lilly using non-GAAP financial measures?

Eli Lilly is using non-GAAP financial measures to provide investors with a better understanding of its ongoing operational performance. These measures exclude certain items (like restructuring costs, asset impairments, and IPR&D charges) that are typically highly variable and can significantly impact reported GAAP results, making period-over-period comparisons more difficult.

What were some of the specific non-GAAP adjustments mentioned for Q2 2008?

For the second quarter of 2008, the non-GAAP adjustments mentioned include $88.9 million in restructuring (exit costs) and other special charges, $57.1 million in asset impairments related to manufacturing operations, and $35.0 million in in-process research and development (IPRD) charges associated with a licensing arrangement with TransPharma Medical Ltd.

What should investors consider regarding the non-GAAP information presented?

Investors should consider the non-GAAP information in addition to, and not as a substitute for or superior to, the financial measures prepared in accordance with U.S. Generally Accepted Accounting Principles (GAAP). The company emphasizes that these non-GAAP measures are used internally by management and are provided to help evaluate ongoing operations and identify trends.

LLY 8-K: Earnings & Results

Summary

Eli Lilly and Company (LLY) filed an 8-K on July 24, 2008, to report its second-quarter 2008 financial results. The filing highlights the company's use of non-GAAP financial measures to provide a clearer view of its ongoing operations, excluding certain significant items. These adjustments are intended to help investors better understand performance trends by removing the impact of restructuring costs, asset impairments, and in-process research and development (IPRD) charges that can be volatile and difficult to predict. The company provided updated financial expectations for the full year 2008, also on both a GAAP and non-GAAP basis. The use of these non-GAAP measures is intended to facilitate meaningful period-over-period comparisons and internal performance evaluations by management. Investors are encouraged to consider this non-GAAP information alongside, not as a replacement for, GAAP-based financial measures.

Key Highlights

1Eli Lilly issued a press release on July 24, 2008, detailing its Q2 2008 financial results.
2The company is providing non-GAAP financial information to present a clearer picture of ongoing operations.
3Significant items impacting GAAP results include restructuring charges, asset impairments, and in-process R&D charges.
4Specific Q2 2008 charges mentioned are $88.9 million for restructuring, $57.1 million for asset impairments, and $35.0 million for IPR&D related to TransPharma Medical Ltd.
5The filing references previously disclosed items affecting prior periods in 2007 and early 2008 to explain the basis for non-GAAP adjustments.
6Lilly provided updated full-year 2008 financial expectations on both GAAP and non-GAAP bases.
7The press release and related financial statements are attached as Exhibit 99 to the 8-K filing.

ELI LILLY & Co 8-K Report, Financial Results (Jul 24, 2008)

Summary

Key Highlights

Frequently Asked Questions